Pyxis Oncology Files Definitive Proxy Statement
Ticker: PYXS · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1782223
| Field | Detail |
|---|---|
| Company | Pyxis Oncology, Inc. (PYXS) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance
Related Tickers: PYXS
TL;DR
Pyxis Oncology's proxy statement is out - time to vote on board members and auditors.
AI Summary
Pyxis Oncology, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key details regarding director nominations and the appointment of its independent registered public accounting firm are expected to be presented.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine filing for a proxy statement, providing information for an upcoming shareholder meeting.
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Registrant
- 0000950170-25-059573 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement required by the SEC, providing shareholders with information to vote on matters at the company's annual meeting.
Who is the registrant for this filing?
The registrant is Pyxis Oncology, Inc.
When was this filing submitted?
This filing was submitted on April 29, 2025.
What is the company's Standard Industrial Classification code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's business address?
The company's business address is 321 Harrison Avenue, Boston, MA 02118.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Pyxis Oncology, Inc. (PYXS).